

**MedInvent announces first publication of a study demonstrating the use of the NasoNeb® Nasal Nebulizer to deliver antibiotics to chronic rhinosinusitis sufferers**

**October 31, 2015. Medina, OH:** MedInvent, LLC is pleased to announce the publication of the first study to use the NasoNeb® Nasal Nebulizer to deliver antibiotics to chronic rhinosinusitis (CRS) sufferers.

This study was conducted as an adjunct to an on-going randomized-control trial comparing oral vs topical antibiotics for acute exacerbations of CRS (<http://clinicaltrials.gov/show/NCT01988779>). The study demonstrated a statistically-significant reduction in bacterial count as well as an increase in bacterial diversity immediately after treatment.

The citation for the study is: Merkley, MA, Bice TC, Grier A, Strohl, AM, Man L-X, Gill, SR: "The effect of antibiotics on the microbiome in acute exacerbations of chronic rhinosinusitis", *Int. Forum Allergy Rhinol.* 2015;5:884-893.

The NasoNeb Nasal Nebulizer is available via prescription. The patented NasoNeb Nasal Nebulizer has been shown to deliver a high concentration of medication throughout the nasal and paranasal sinus cavities in two university-based studies. In a separate university-based study, NasoNeb-delivered Budesonide demonstrated positive outcomes from baseline to endpoint in both objective and subjective outcomes measures in a group of perennial allergic rhinitis patients. In an additional study, NasoNeb-delivered agents demonstrated improved CSF flow in an ovine model of hydrocephalus.

For more information, please contact us at 330-247-0921 or visit the NasoNeb website at [www.nasoneb.com](http://www.nasoneb.com).

**About MedInvent, LLC**

MedInvent, LLC is a privately-held limited liability corporation established in 2008 with operations in Medina, OH. MedInvent develops and markets the NasoNeb Family of drug delivery systems for the topical delivery of medication to the nasal and paranasal sinus cavities. The NasoNeb Nasal Nebulizer is indicated for drug delivery to the nasal cavity for drugs formulated for inhalation. For more information, visit [www.nasoneb.com](http://www.nasoneb.com)

*This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risk. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.*